FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT House Committee Approves User Fee Bill [492 Words]
05/10/2012
 
 
TXT Stakeholders Bombard FDA with Biosimilars Ideas [874 Words]
05/11/2012
 
 
TXT FDA Has ‘Threats to Power, Stability’: Professor [539 Words]
05/09/2012
 
 
TXT Hamburg Wants to Share ‘Protected’ Industry Data with Public [889 Words]
05/08/2012
 
 
TXT Court Nullifies 1999 Abbott Consent Decree [329 Words]
05/10/2012
 
 
TXT Abbott Smacked with 2nd Largest Fine Ever [708 Words]
05/07/2012
 
 
TXT Abbott Petition Seeks Block on Biosimilar Approvals [1267 Words]
04/30/2012
 
 
TXT PDUFA 4 Eased, Increased Regulatory Burden: Tufts [374 Words]
05/09/2012
 
 
TXT Genentech Cited on Avastin GMP Deviations [212 Words]
05/11/2012
 
 
TXT FDA-483 Documents Issues at RJL Systems [109 Words]
05/09/2012
 
 
TXT FDA Details 7 Inspection Observations at Beckman Coulter [125 Words]
05/09/2012
 
 
TXT Senators Seek GAO Probe on DEA Efforts in Worsening Drug Shortages [131 Words]
05/07/2012
 
 
TXT Since Our Last Issue ... [375 Words]
05/13/2012
 
 
TXT Product Approval Summaries [430 Words]
05/13/2012
 
 
TXT Latest FDA Federal Register Notices [1060 Words]
05/13/2012
 
 
TXT FDA Panel Backs Truvada in HIV Prevention [102 Words]
05/11/2012
 
 
TXT FDA Mulls ‘False’ Test Results with In-home HIV Test Kit [259 Words]
05/11/2012
 
 
TXT Quality Issues in Boehringer Inspection [136 Words]
05/10/2012
 
 
TXT Advisors Back Arena’s Lorcaserin for Weight Loss [65 Words]
05/10/2012
 
 
TXT Latest FDA Warning Letters [322 Words]
05/08/2012
 
 
TXT Uses of Clinical Outcome Assessments Explained [143 Words]
05/08/2012
 
 
TXT Akorn Marketing Unapproved Ophthalmic Products: Alcon [190 Words]
05/08/2012
 
 
TXT Second Primary Malignancy Warning on Revlimid [114 Words]
05/07/2012
 
 
TXT Agency Cites Dendreon GMPs in FDA-483 [91 Words]
05/07/2012
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving